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The Newborn screening programme (NBS) by MS/MS – 2004 -2012      737 902 newborns 
screened 
 
 
4 cases of Carnitine palmitoytransferase II deficiency (CPTII ) were detected by NBS 
1 remains without a definitive diagnostic. 
                                                                                                                                                                        
                                                                                       
                                                                                        Prevalence 1:245 967 in Portugal 
 
 
Substimated prevalence ? The myopathic form may not be detected 
This enzymatic complex is made up of two distinct proteins named carnitine 
palmitoyltransferase I (CPTI) and II (CPTII) 
Catalyzes the formation 
of acylcarnitine from 
carnitine and acil-CoA 
Catalyses the formation 
of acil-CoA from 
acylcarnitine and CoA 
for the β-oxidation 
process.   
 
METABOLIC PATHWAY 
CPTI 
CPTII 
The mitochondrial CPT system 
 
A CPTII deficiency is a autosomal recessive inherited disorder of fatty acid metabolism.  
 
Organic acids profile - Acumulation of long chain acylcarnitines in mitochondrial matrix – 
metabolic pathway of peroxisomal b-oxidation. Most of these cases with a normal 
profile. 
 
 Histological investigation (muscle) 
- Normal or shows mild unspecific myophatic changes -  heterozygotes 
- Lipid accumulation - homozygotes  
 
Differencial diagnosis – carnitine-acylcarnitine translocase deficiency (CACT) 
 
Existence of symptomatic heterozygous patients 
 
Clinical heterogeneity 
CPTII DEFICIENCY 
CLINICAL PHENOTYPES 
Lethal neonatal form  
 MIM#608836  
Severe infantile 
hepatocardiomuscular form 
MIM#600649  
Liver failure  
 
hypoketotic 
hypoglycemia 
 
Cardiomyopathy 
 
Seizures and coma 
after fasting or 
infection 
 
Facial abnormalities 
or structural 
malformations (e.g., 
cystic renal) 
Seizures 
hypoketotic 
hypoglycemia 
Cardiomyopathy 
 
Peripheral 
myopathy 
 
Attacks of 
abdominal pain 
and headache 
Myopathic form  
MIM#255110 
Attaks of myalgia 
accompanied by 
myoglobinuria 
 
Rhabdomyolysis 
(triggered by extensive 
exercice, cold, fever or  
prolonged fasting or 
stress) 
 
Usually no signs of 
myopathy (weakness, 
myalgia, elevation of 
serum creatine kinase [CK] 
concentration) between 
attacks 
 
May be under-recognized 
Lethal neonatal form  
 MIM#608836  
Severe infantile 
hepatocardiomuscular form 
MIM#600649  
Myopathic form  
MIM#255110 
Severe 
Severe 
         “Mild” 
 
Variable 1st to 6th 
decade 
Sudden 
death (SIDS) 
AGE OF ONSET 
Compound heterozygosity  of 
mild and severe mutations 
has been reported whith this 
form  
S113L accounts for 60% 
of mutant alleles  
CPTII PROTEIN 
Localized in the inner  
mitochondrial membrane 
 
Catalytically active  
 
 
GENE 
CPT2 
Cr.- 1p32 
cDNA has 1974 bp 
5 exons 
658 amino acids 
20 Kb 
86 described mutations 
Skeletal muscle 
Liver 
Fibroblasts  
Lymphocytes 
Patients  
 
Over a 8 years period, 737 902 newborns were screened by blood spots 
 
4 newborns were detected through newborn screening (NBS) by 
   acylcarnitine profile 
5 cases with clinical symptoms suggestive of CPTII deficiency 
 
Methods 
Tandem mass spectrometry (MS/MS) by API 2000 triple quadrupole 
Molecular analysis of CPT 2 gene was done by direct sequencing 
 
PATIENTS  AND METHODS 
MASS SPECTROMETRY OF ACYLCARNITINE PROFILE 
A typical profile of CPTII deficiency 
C0 
C2 
C16 
C18:1 
C18 
 
 
 
 
 
 
 
 C16 Palmitoylcarnitine  
 
 C18:1 Octadecenoylcarnitine 
 
  C0/(C16+C18) 
 
(C16+C18:1)/C2 
 
 
 
May be ambiguous for myophatic form 
RESULTS 
Newborn screening cases 
Case 
 
 
Age 
C0 
µM 
C2 
µM 
C16 
µM 
C18 
µM 
C18:1 
µM 
C0/ 
C16+18 
C16+ 
C18:1/C2 
Allele 1 Allele 2 
Rf>9.13 Rf>7.0 Rf<7.99 Rf<2.28 Rf<3.42 Rf>3.0 Rf<0.5 
1 M 4 d 15.1 7.02 7.02 2.42 2.7 1.6 1.38 
c.430_435delGAGTAT 
(p.E144-Y145del) 
c.725_726insA 
(p.H242Qfs*14) 
2† M 2 d 17.7 9.1 31.07 9.24 11.6 0.44 4.76 
c.110_111dupGC 
(p.36_38insGC) 
c.110_111dupGC 
(p.36_38insGC) 
3 M 6 d 14.94 10.71 7.22 3.13 4.21 1.44 1.07 Under study Under study 
4 M 5 d 10.3 7.7 6.8 2.9 4.4 1.06 1.5 c.680C>T (p.227L) c.1106A>G (p-H369R) 
- Novel mutations 
All cases   -   C18 and C18:1 
                      Co/C16+C18 and C16+C18:1/C2 
    
Symptomatic cases 
Case 
 
 
Age of  
Onset 
(years) 
C0 
µM 
C2 
µM 
C16 
µM 
C18 
µM 
C18:1 
µM 
Allele 1 Allele 2 
Rf>19.24 Rf>8.06 Rf<2.09 Rf<1.36 Rf<2.33 
5 M 52 55.01 14.55 0.8 0.67 1.25 c.1025T>C (p.M342T) Wild-type 
6 M 2  1.75 3.42 1.18 0.85 1.11 c.359A>G (p.Y120C) c.1412T>G (p.F471C) 
7 M 35 na na na na na c.338C>T (p.S113L) c.274G>A (p.G92R) 
8 F 15  19.2 4.71 0.75 0.69 0.86 c.338C>T (p.S113L) 
c.[1032T>G;1037delA] 
(p.H344Q;D346Vfs*73) 
9 F 2  12.3 4.42 2.63 1.38 2.85 c.338C>T (p.S113L) c.338C>T (p.S113L) 
- Novel mutations 
- All cases with two mutations -  C2 (β-oxidation) 
- Case 5  C2 normal: symptomatic heterozigotic (dominant-negative mutation / Synergistic heterozygosity) 
- Case 9  NBS normal.    2 years – C2  and C16 C18 C18:1  Myopathic form (father is S113L/S113L) 
RESULTS 
1 2 3 4 5 
E144_Y145del 
H242QfsX14 
H344Q;D346Vfs*73 
G92R M342T 
H369R 
F471C 
- 11 mutations: 7 novel mutations - 2 frameshift, 1 deletion and 4 missense + 4 reported 
- V368I and M647V polymorphism found in must patients (may impair the enzymatic activity) 
4 missense novel mutations were classified as pathogenic by prediction softwares – 
Polyphen 2, SIFT and Mutation taster 
MUTATIONS IN CPT2 GENE 
      
 Example 
 
Case 1 
 two novel mutations 
    p.E144-Y145del/p.H242Qfs*14 
                                          
                               256 amino acids 
 
Enzymatic act. ↓(8,5%) 
4 days asymptomatic 
Molecular characterization – additional relevance 
The identification of severe mutations should alert the 
clinicians for the careful follow-up of these patients 
CONCLUSIONS 
Our results support that newborn screening can efficiently detect 
infantile CPT II deficiency and allows an early intervention. 
   
NBS may be less effective in detecting myophatic forms. 
 
The molecular characterization allow the definitive diagnostic in CPTII 
deficiency and may help the clinicians to define the prognostic of the 
clinical phenotype and  prenatal diagnosis.   
 
Thank you! 
